You can also call the appointment center to schedule, change or cancel an appointment or ask questions.
Clinical trials are studies, managed by government agencies, educational institutions, private not-for-profit organizations, or commercial businesses, to develop, produce and evaluate the effectiveness of new treatments and therapies for diseases.
Beaumont’s urology department is focused on urologic disease research to develop, produce and evaluate the effectiveness of new, innovative approaches to treatment that may improve patient outcomes and quality of life. Areas of research interest and expertise cover a wide range of urologic diseases.
Individuals who participate in research studies are given the opportunity to benefit from treatments that are not currently available to the general public, but have shown promise in previous research.
Risks from participating in a clinical trial vary depending on the study. It is important to understand that not all new treatments produce the desired effect.
This study will assess the response to the micro-needle patch electrode stimulation of the posterior tibial nerve using the Biowave device in women 18 years of age and older with overactive bladder symptoms. The investigator hypothesizes that after at least 6 weekly treatments there will be modest improvements in overactive bladder symptoms trending toward more improvement.
Sponsor – Physician Initiated
For more information, visit http://clinicaltrials.gov/ct2/show/NCT01848366
The purpose of the study is to evaluate if LiRIS 400 mg is safe and tolerable when administered to women with Interstitial Cystitis (IC) with Hunner's lesions, and to evaluate any change in the bladder or in IC symptoms, following LiRIS administration. Women 18 years and older with moderate to severe bladder discomfort may be considered as potential candidates. LiRIS® 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the bladder for up to 14 days gradually releasing lidocaine, and removed from the bladder via cystoscopy.
Sponsor – Taris Biomedical, Inc.
For more information, visit http://clinicaltrials.gov/show/NCT01879683
The purposes of the study is to determine if LiRIS®, an investigational drug-delivery system, is safe and tolerable in women 18 years of age and older with Interstitial Cystitis (IC), and to evaluate any change in IC symptoms following LiRIS administration. The study is conducted in 2 parts: a randomized, blinded part in which subjects are assigned randomly (by chance) to LiRIS 400 mg or LiRIS placebo; subjects who complete this part and are eligible to continue, may participate in the open-label part in which all subjects receive LiRIS 400mg. In both parts of the study (blinded and open-label), LiRIS is inserted into the bladder during cystoscopy, remains in the bladder for 14 days, and is removed during cystoscopy.
For more information, visit http://clinicaltrials.gov/ct2/show/NCT01824303
This study will evaluate the safety and efficacy of onabotulinumtoxinA for the treatment of urinary incontinence due to neurogenic detrusor (bladder muscle) overactivity in pediatric patients from the age of 8 to 17 years. This study is for children who regularly using clean intermittent catheterization to empty their bladders. The study medication is injected into the bladder during cystoscopy.
Sponsor – Allergan
For more information, visit http://clinicaltrials.gov/show/NCT01852045
To inquire about any of these or other studies, please call the Urology Research study hotline at 248-551-3355 or the department of Urology Research at 248-551-3565.